Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Teva Pharmaceutical (TEVA)

39.65

+0.12 (0.30%)

as of Oct 5, 2026, 7:59:59 pm Market Open.

71 watching

TOP PICK

Primarily a generic drug manufacturer. Market has overreacted with the challenge it is facing with from a competitor on one of its branded drugs. 1.5% yield.

BUY ON WEAKNESS

Leading generic drug manufacturer globally. Good growth profile. Valuations in the $40-$50 range would be decent. Growth rate is in the high mid-teens too low $20's.

DON'T BUY

Global leader with about 60% of revenues from US. Generics have recently under performed because of regulatory changes that are squeezing profitability. Generics will continue to expand market share. Acquisitions can take time for results to show in the numbers. Trading below 200 day moving average. Would prefer to see if trading above $60.

HOLD

Owns half as much as he used to. Worried about their biggest non-generic product. It’s an MS drug with a lot of controversy.

COMMENT

Generic drugs are going to thrive. Cost of drugs is killing global governments that pay for them. The solution is generics that typically cost a fraction. He is wary of the entire pharmaceutical industry.

TOP PICK

Likes the generic space. Expects there will be increasing appetite for governments globally to spend less on health care. Have some very aggressive growth targets for the next 4-5 years. Have been very good at doing acquisitions.

PAST TOP PICK

(A Top Pick May 6/09. Up 37% excluding dividends.) Largest global generic manufacturer. Made acquisitions that strengthens them geographically. Trend towards generics is going to continue.

TOP PICK

Largest manufacturer of generic drugs. Have a pipeline potential of over $100 billion over the next 5 years as patents come off from large pharmaceuticals. Seriously undervalued.

DON'T BUY

Half business is generic drugs. US health care companies are reporting. New US reform will cause increased rebates to Medicaid. This is primary reason for TEVA coming off along with the group.

COMMENT

Generics continue to get wins in terms of shortened time frames as to pharmaceuticals staying on patents.

PAST TOP PICK

(A Top Pick Jan 28/09. Up 34.77%.) Buy on weakness.

TOP PICK

Dominant generics player globally. Has 25% of the generic market in the US. Expecting some form of health care will pass in the US, which will bring 20-40 million people into the health-care system. Trading at only about 15X earnings. Very strong growth prospects.

PAST TOP PICK

(A Top Pick Nov 11/08. Up 24.69%.) Still likes.

BUY

More and more major drugs are coming off patent over the next few years. Being the biggest they will get the lion’s share.

TOP PICK

(A Top Pick May 11/09. Up 12.75%.) Has been in a great uptrend for many years. Thinks you will be able to buy this on a pullback within the next 30 days or so. Fundamentals are good on this company.

Showing 181 to 195 of 279 entries

Most Recent Experts

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Bruce Murray

The Murray Wealth Group

Dennis Mitchell, CFA

Sentry Select Capital Corp

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Teva Pharmaceutical (TEVA)